Amicus Therapeutics (FOLD) Tops Q3 EPS by 3c, Beats on Revenue

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $169.06 million versus the consensus estimate of $165.44 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit